DE

Journey Medical CorpNASDAQ DERM Stock Report

Last reporting period 30 Jun, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

0.108

Micro

Exchange

XNAS - Nasdaq

DERM Stock Analysis

DE

Uncovered

Journey Medical Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

18/100

Low score

Market cap $B

0.108

Dividend yield

Shares outstanding

17.643 B

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The firm is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes over seven branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products that have been approved by the United States Food and Drug Administration (FDA) for sale include Qbrexza, Accutane, Targadox, Ximino, and Exelderm Cream and Solution. The firm's product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne, and Exelderm Cream and Solution is an antifungal intended for topical use.

View Section: Eyestock Rating